Clinical Trial Detail

NCT ID NCT03118349
Title Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors MabVax Therapeutics, Inc.
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

Therapies

MVT-1075 + MVT-5873

Age Groups: adult senior

No variant requirements are available.